Pharmacogenetics: Clinical Applications and Cases Across the Lifespan


What are the current dosing guidelines for the implementation of pharmacogenetics into practice?

Groups such as the Clinical Pharmacogenetics Implementation Consortium and the US Food and Drug Administration (FDA) have developed guidelines supporting the implementation of pharmacogenetics into practice. However, many mental health clinicians are either unfamiliar with or uncertain about these guidelines, the evidence supporting their development, or the circumstances in which they should be employed.

Join Psychiatric TimesTM Board Member Helen Lavretsky, MD, MS, and colleagues Daniel J. Mueller, MD, and Chad Bousman, PhD, for “Pharmacogenetics: Clinical Applications and Cases Across the Lifespan” during the American Psychiatric Association Annual Meeting on Tuesday, May 24, 2022, at 10:30am. The presentation will feature an overview of the current guidelines; the pharmacogenetic evidence connected to common psychiatric medications; and some recent clinical cases and studies supporting the efficacy of pharmacogenetics in psychiatric care delivery across the lifespan.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
© 2024 MJH Life Sciences

All rights reserved.